Single Sided Deafness: An Evidence-Based Review of Expanding Treatment Options (AMW) Session
2021 AAO-HNSF Annual Meeting & OTO Experience
With its diverse etiologies, demographic variability, and the already large and ever-expanding armamentarium of options available for its treatment, unilateral profound hearing loss (single-sided deafness, SSD) becomes a difficult problem for otolaryngologists, audiologists, and advanced practice providers to treat, specifically as it relates to which rehabilitative option is best for their patients. This discussion will review the various management options for SSD in both the adult and pediatric population with a special focus on an evidence-based approach through accumulated data and reported outcomes. Although we will briefly review key elements of the workup necessary for patients with SSD, the primary emphasis will be placed on specific options available to treat. The review will include traditional amplification instruments (i.e., contralateral routing of signal (CROS) hearing aid), bone-conduction osseointegrated devices (including both transcutaneous and percutaneous options), and finally cochlear implantation.
Description
Learning Objective: 1. Compare the variety of rehabilitative options available for the treatment of SSD. 2. Understand the differences in both speech perception and binaural processing outcomes between different devices. 3. Discuss the variables that may be predictive of success for cochlear implantation in the treatment of unilateral profound hearing loss/SSD.Compare the variety of rehabilitative options available for the treatment of SSD. Faculty: Daniel Zeitler, MD(Consulting Fee: Advanced Bionics Corporation, MedEl Corporation, Oticon Medical, Stryker; Research Funding: Advanced Bionics Corporation), Ashkan Monfared, MD(Nothing to Disclose), Soha Ghossaini, MD(Honoraria: MedEl), Samuel Spear, MD(Nothing to Disclose).